Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

ER - Inify Laboratories: Continued strong growth - construction and establishment in the UK

Company: Inify Laboratories AB Date: 2025-04-30 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 Inify Laboratories: Continued strong growth - construction and establishment in the UK

# Inify Laboratories: Continued strong growth - construction and establishment in the UK

STOCKHOLM - April 30, 2025 - Inify Laboratories, a unique laboratory service  

that provides cancer diagnostics within pathology, continued to deliver sales  

growth and positive margins in Sweden, alongside steady progress in its UK  

expansion.  

  

"We remain fully focused on growth in Sweden, our UK establishment, and further  

development of our system for gastrointestinal diagnostics," says CEO Fredrik  

Palm, CEO of Inify Laboratories.  

  

Sales in the first quarter amounted to SEK 5.1 million (2.2), representing 130%  

growth compared to the same period in 2024. Cash balance at the end of the  

quarter amounted to SEK 151.1 million, strengthened by the SEK 150 million share  

issue completed in February.  

  

"Our laboratory operations continue to generate positive financial results, with  

further improvement expected as sample volumes grow," says Palm.  

  

During the first quarter, Inify established its initial UK organisation by  

recruiting key personnel for subsidiary management, laboratory operations, and  

sales. Planning for the laboratory construction is progressing well, and the  

company has selecting a modern, newly built property in a business park just  

south of Oxford.  

  

"In parallel with the laboratory establishment, we have an ongoing, close  

dialogue with public (NHS) and private healthcare providers - our future  

customers," said Palm.  

  

Together with its customers, Inify has begun developing new, structured  

processes in prostate cancer diagnostics, delivering superior efficiency and  

quality.  

  

"We are one quarter into what promises to be a very exciting year. Inify is  

growing in Sweden, expanding internationally, and at the same time developing  

new capabilities to broaden our service offering into gastrointestinal  

diagnostics. In short, we are at the forefront of setting a new standard," Palm  

concludes.  

  

For further information, please contact CEO Fredrik Palm,  

fredrik.palm@inify.com, or visit https://www.inify.com  

  

###  

  

The future of pathology  

  

Inify Laboratories provides cancer diagnostics through ultramodern laboratory  

services within pathology. It uses a fully digital, standardised and AI  

\-supported workflow to optimise quality and response times, initially within  

prostate cancer.The concept is scalable and can be extended to other diagnoses.  

The service includes the whole chain of sample handling: from logistics, to  

sample preparation, to reporting by a pathologist. The report is assisted by our  

own AI, proven in clinical studies to have world-leading accuracy. The complete  

workflow is supported by a tailor-made process control system.  

The company, based in Sweden, became independent in 2022 through a spin-off  

fromContextVision (https://www.contextvision.com/), with 40 years of experience  

within digital imaging for medical applications. Its shares are listed  

onEuronext Growth Oslo under the ticker  

INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.